Supporting Information:

Saquayamycins G-K, Cytotoxic Angucyclines from *Streptomyces* sp. Including Two Angucycline Derivatives Bearing Aminosugar Rednose

Khaled A. Shaaban, [†] Tamer A. Ahmed, [†] Markos Leggas, ^{†,‡} and Jürgen Rohr ^{*,†‡}

Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky 40536-0596, USA, and Markey Cancer Center, University of Kentucky, 800 Rose Street, Lexington, Kentucky 40536-0293, USA.

[†] Department of Pharmaceutical Sciences, College of Pharmacy

- [‡] Markey Cancer Center
- * To whom correspondence should be addressed. Tel: +1 859 323 5031 Fax: +1 859 257 7564. E-mail: jrohr2@email.uky.edu

Supporting Information

HPLC analysis of the crude extract obtained from the *Streptomyces* sp. KY40-1; work-up procedure scheme; NMR and mass spectra of isolated angucyclines (**1-8**).





1: $R^1 = I$, $R^2 = X$; Saquayamycin G 2: R¹ = II, R² = XI; Saquayamycin H 3: R¹ = III, R² = X; Saquayamycin I 4: R¹ = II, R² = XII; Saquayamycin J **5**: $R^1 = V$, $R^2 = X$; Saquayamycin K 6: R¹ = II, R² = H; Saquayamycin B1 7: R¹ = IV, R² = X; Saquayamycin A **8**: $\mathbb{R}^1 = \mathbb{I}, \mathbb{R}^2 = X$; Saquayamycin B 9: R¹ = VI, R² = XIII; Saguayamycin C **10:** $R^1 = II$, $R^2 = XIII$; Saquayamycin D 11: R¹ = IV, R² = H; Saquayamycin A1 12: R¹ = VI, R² = H; Saquayamycin C1 13: R¹ = IV, R² = XIII; Saguayamycin E **14:** $R^1 = VI$, $R^2 = X$; Saquayamycin F 15: R¹ = VIII, R² = VII; Saquayamycin Z **16:** R¹ = IX, R² = H; A-7884 **17**: $R^1 = I$, $R^2 = H$; Aquayamycin



18: R¹ = II, R² = X; Moromycin A **19:** R¹ = II, R² = H; Moromycin B

Contents	Page
Figure S1: Work-up procedure of extracts from the <i>Streptomyces</i> sp. KY40-1	S 5
Figure S2: UV (MeOH) spectra of the new Saquayamycins G-K (1-5) and Saquayamycin B1 (6) in comparison with Saquayamycin B (8)	S 6
Figure S3: ¹ H- ¹ H-COSY (bold lines) and selected HMBC (\rightarrow) couplings in Saquayamycin A (7)	S 6
Figure S4: Selected NOESY correlations (\leftrightarrow) of Saquayamycin A (7)	S 7
Figure S5: ¹ H- ¹ H-COSY (bold lines) and selected HMBC (\rightarrow) couplings in Saquayamycin B (8)	S 7
Figure S6: Selected NOESY correlations (\leftrightarrow) of Saquayamycin B (8)	S 7
Figure S7: A) The Streptomyces sp. KY40-1 was cultivated on M2-agar plates at 28 °C for 3 days; B) A 100 ml of the reddish brown culture broth from Streptomyces sp. KY40-1 after inoculation and cultivation at 28 °C (250 rpm) for 48 hrs on SG-medium. C) Large scale cultivation (6 L) of Streptomyces sp. KY40-1 after inoculation using grown 100 mL preculture, at 28 °C (250 rpm) for 4 days on SG-medium. D) TLC (DCM/5% MeOH) of the water phase and mycelium extracts obtained from the 6 L cultivation of Streptomyces sp. KY40-1.	S8
Figure S8: PTLC (20 x 20 cm) separation of Saquayamycins J (4) and K (5) using <i>n</i> -hexane/60% EtOAc.	S 9
Figure S9: HPLC analysis of the crude extract obtained from the <i>Streptomyces</i> sp. KY40-1 strain, the detection wavelength was 300 nm. Solvent A: H ₂ O, solvent B: acetoni-trile; flow rate: 0.5 mLmin ⁻¹ ; 0–15 min, 75-0% A (linear gradient), 15–24 min 0% A and 100 % B, 24–26 min 0-75% A (linear gradient), 26–29 min 75% A.	S10
Figure S10: (-)-HRESI-MS spectrum of Saquayamycin G (1)	S 11
Figure S11: (-)-HRESI-MS spectrum of Saquayamycin G (1)	S12
Figure S12: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin G (1)	S13
Figure S13: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin G (1)	S14
Figure S14: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin G (1)	S15
Figure S15: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin G (1)	S16
Figure S16: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin G (1)	S17
Figure S17: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin G (1)	S18
Figure S18: (-)-HRESI-MS spectrum of Saquayamycin H (2)	S19
Figure S19: (-)-HRESI-MS spectrum of Saquayamycin H (2)	S20
Figure S20: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin H (2)	S21
Figure S21: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin H (2)	S22
Figure S22: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin H (2)	S23
Figure S23: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin H (2)	S24
Figure S24: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin H (2)	S25
Figure S25: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin H (2)	S26
Figure S26: ¹ H NMR spectrum (Acetone- <i>d</i> ₆ , 500 MHz) of Saquayamycin I (3)	S27
Figure S27: ¹³ C NMR spectrum (Acetone- d_6 , 125 MHz) of Saquayamycin I (3)	S28
Figure S28: ¹ H- ¹ H COSY spectrum (Acetone- <i>d</i> ₆ , 500 MHz) of Saquayamycin I (3)	S29
Figure S29: HSQC spectrum (Acetone- d_6 , 500 MHz) of Saquayamycin I (3)	S 30

Figure S30: HMBC spectrum (Acetone-d ₆ , 500 MHz) of Saquayamycin I (3)	S 31
Figure S31: NOESY spectrum (Acetone-d ₆ , 500 MHz) of Saquayamycin I (3)	S32
Figure S32: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin J (4)	S33
Figure S33: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin J (4)	S34
Figure S34: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin J (4)	S35
Figure S35: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin J (4)	S36
Figure S36: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin J (4)	S37
Figure S37: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin J (4)	S38
Figure S38: (-)-HRESI-MS spectrum of Saquayamycin K (5)	S39
Figure S39: (-)-HRESI-MS spectrum of Saquayamycin K (5)	S40
Figure S40: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin K (5)	S41
Figure S41: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin K (5)	S42
Figure S42: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin K (5)	S43
Figure S43: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin K (5)	S44
Figure S44: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin K (5)	S45
Figure S45: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin K (5)	S46
Figure S46: (-)-HRESI-MS spectrum of Saquayamycin B1 (6)	S47
Figure S47: (-)-HRESI-MS spectrum of Saquayamycin B1 (6)	S48
Figure S48: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B1 (6)	S49
Figure S49: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin B1 (6)	S 50
Figure S50: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B1 (6)	S51
Figure S51: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B1 (6)	S52
Figure S52: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B1 (6)	S53
Figure S53: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B1 (6)	S54
Figure S54: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin A (7)	S55
Figure S55: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin A (7)	S56
Figure S56: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin A (7)	S57
Figure S57: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin A (7)	S58
Figure S58: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin A (7)	S59
Figure S59: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin A (7)	S 60
Figure S60: ¹ H NMR spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B (8)	S61
Figure S61: ¹³ C NMR spectrum (CDCl ₃ , 125 MHz) of Saquayamycin B (8)	S62
Figure S62: ¹ H- ¹ H COSY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B (8)	S63
Figure S63: HSQC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B (8)	S64
Figure S64: HMBC spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B (8)	S65
Figure S65: NOESY spectrum (CDCl ₃ , 500 MHz) of Saquayamycin B (8) Figure S66: Dose response curve of saquayamycins G-J (1-4), in comparison with landomycin A	S66
in a prostate cancer cell line (PC3) at 48 h.	S67
Figure S67: Dose response curve of C) saquayamycins G-J (1-4), and D) saquayamycins K, B1, A and B (5-8); in comparison with landomycin A (H460)	S67



Figure S1: Work-up procedure of extracts from the Streptomyces sp. KY40-1

Figure S2: UV (MeOH) spectra of the new Saquayamycins G-K (1-5) and Saquayamycin B1 (6) in comparison with Saquayamycin B (8)

Figure S3: ¹H-¹H-COSY (bold lines) and selected HMBC (\rightarrow) couplings in saquayamycin A (7)

Figure S4: Selected NOESY correlations (\leftrightarrow) of saquayamycin A (7)

Figure S5: ¹H-¹H-COSY (bold lines) and selected HMBC (\rightarrow) couplings in saquayamycin B (8)

Figure S6: Selected NOESY correlations (\leftrightarrow) of saquayamycin B (8)

Figure S7: A) The *Streptomyces* sp. KY40-1 was cultivated on M2-agar plates at 28 °C for 3 days; **B**) A 100 ml of the reddish brown culture broth from *Streptomyces* sp. KY40-1 after inoculation and cultivation at 28 °C (250 rpm) for 48 hrs on SG-medium. **C**) Large scale cultivation (6 L) of *Streptomyces* sp. KY40-1 after inoculation using grown 100 mL preculture, at 28 °C (250 rpm) for 4 days on SG-medium. **D**) TLC (DCM/5% MeOH) of the water phase and mycelium extracts obtained from the 6 L cultivation of *Streptomyces* sp. KY40-1.

Figure S9: HPLC analysis of the crude extract obtained from the *Streptomyces* sp. KY40-1 strain, the detection wavelength was 300 nm. Solvent A: H₂O, solvent B: acetonitrile; flow rate: 0.5 mLmin⁻¹; 0–15 min, 75-0% A (linear gradient), 15–24 min 0% A and 100 % B, 24–26 min 0-75% A (linear gradient), 26–29 min 75% A.

Max. 3.5e5 counts

Figure S10: (-)-HRESI-MS spectrum of saquayamycin G (1)

Figure S11: (-)-HRESI-MS spectrum of saquayamycin G (1)

Figure S12: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin G (1)

Figure S13: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin G (1)

Figure S14: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin G (1)

Figure S15: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin G (1)

Figure S16: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin G (1)

KS_KY40-1_F3A_NOESY_CDC13_11_21_2010 CDC13, 500 MHz, nt=4, time=4:33 hrs Khaled A. Shaaban Sample: Khaled_A_Shaaban File: home/khaled/vnmrsys/data/KS_KY40-1_F3A_NOESY_CDCl3_11_21_2010.fid Pulse Sequence: NOESY F2 (ppm) 7-. 13-F1 (ppm)

Figure S17: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin G (1)

Figure S18: (-)-HRESI-MS spectrum of saquayamycin H (2)

Max. 1.5e5 counts

■ -TOF MS: 2.508 to 2.617 min from KSKY40-1-F4D2.wiff Agilent

Figure S19: (-)-HRESI-MS spectrum of saquayamycin H (2)

S20

Max. 1.5e5 counts.

Figure S20: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin H (2)

Figure S21: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin H (2)

Figure S22: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin H (**2**)

Figure S23: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin H (2)

Figure S24: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin H (2)

Figure S25: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin H (2)

Figure S26: ¹H NMR spectrum (acetone- d_6 , 500 MHz) of saquayamycin I (**3**)

Figure S27: ¹³C NMR spectrum (acetone- d_6 , 125 MHz) of saquayamycin I (3)

Figure S28: 1 H- 1 H COSY spectrum (acetone- d_{6} , 500 MHz) of saquayamycin I (**3**)

Figure S29: HSQC spectrum (acetone- d_6 , 500 MHz) of saquayamycin I (3)

Figure S30: HMBC spectrum (acetone- d_6 , 500 MHz) of saquayamycin I (**3**)

Figure S31: NOESY spectrum (acetone- d_6 , 500 MHz) of saquayamycin I (**3**)

KS_KY40-1_F1C3B_1HNMR_CDC13_12_17_2010
CDC13, 500 MHz, nt=32
Khaled A. Shaaban

Figure S32: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin J (4)

Figure S33: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin J (4)

Figure S34: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin J (4)

Figure S35: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin J (4)

KS_KY40-1_F1C3B_GHMBC_CDC13_12_27_2010 CDC13, 500 MHz, time=10:37 hrs Khaled A. Shaaban

Sample: khaled_A_Shaaban File: xp

Figure S36: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin J (4)

Figure S37: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin J (4)

Figure S38: (-)-HRESI-MS spectrum of saquayamycin K (5)

Max. 8.3e4 count

■ -TOF MS: 1.257 to 1.365 min from KSKY40-1-F1C3A.wiff Agilent

Figure S39: (-)-HRESI-MS spectrum of saquayamycin K (5)

Figure S40: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin K (5)

Figure S41: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin K (5)

Figure S42: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin K (5)

Figure S43: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin K (5)

Figure S44: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin K (5)

Figure S45: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin K (5)

Max. 3.3e5 coun

Figure S46: (-)-HRESI-MS spectrum of saquayamycin B1 (6)

■ -TOF MS: 1.020 to 1.128 min from KSKY40-1-F1C2B.wiff Agilent

Max. 3.3e5 counts

Figure S47: (-)-HRESI-MS spectrum of saquayamycin B1 (6)

Figure S48: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin B1 (6)

Figure S49: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin B1 (6)

Figure S50: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin B1 (6)

CDC13, 500 MHz, nt=8, time=5 hrs Khaled A. Shaaban Sample: Khaled_A_Shaaban File: xp Pulse Sequence: gHSQC F2 (ppm) 2-3-4-5-7-8-F1 (ppm)

Figure S51: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin B1 (6)

CDC13, 500 MHz, nt=32, time=10:37 hrs Khaled A. Shaaban

Sample: Khaled_A_Shaaban File: xp

Pulse Sequence: gHMBC

Figure S52: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin B1 (6)

Figure S53: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin B1 (6)

Figure S54: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin A (7)

Figure S55: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin A (7)

Figure S56: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin A (7)

Figure S57: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin A (7)

Figure S58: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin A (7)

Figure S59: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin A (7)

Figure S60: ¹H NMR spectrum (CDCl₃, 500 MHz) of saquayamycin B (8)

Figure S61: ¹³C NMR spectrum (CDCl₃, 125 MHz) of saquayamycin B (8)

Figure S62: ¹H-¹H COSY spectrum (CDCl₃, 500 MHz) of saquayamycin B (8)

Figure S63: HSQC spectrum (CDCl₃, 500 MHz) of saquayamycin B (8)

Figure S64: HMBC spectrum (CDCl₃, 500 MHz) of saquayamycin B (8)

Figure S65: NOESY spectrum (CDCl₃, 500 MHz) of saquayamycin B (8)

Figure S 66: Dose response curve of **A**) saquayamycins G-J (1-4), and **B**) saquayamycins K, B1, A and B (5-8); in comparison with landomycin A in a prostate cancer cell line (PC3) at 48 h.

Figure S67: Dose response curve of **C**) saquayamycins G-J (1-4), and **D**) saquayamycins K, B1, A and B (5-8); in comparison with landomycin A in a non-small lung cancer cell line (H460) at 48 h.